Newscast – Page 182 – media

FDA approval granted to Emmaus for sickle cell therapy

Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
- Source: fiercebiotech
- 537
- June 9, 2017
Company Insight FDA therapy
Aspen Pharmacare hit by EU antitrust cancer drug price probe

Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
- Source: pharmatimes
- 599
- May 16, 2017
cancer Company Insight EU
One in three RA patients rejecting meds because of cost

One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
- Source: pharmatimes
- 532
- May 14, 2017
Market Views NRAS PPC
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 593
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 581
- May 10, 2017
antibody Bavencio cancer New Approvals
GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
- Source: pharmatimes
- 580
- May 8, 2017
asthma Company Insight therapy
WHO improves transparency of financial data

WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
- Source: pharmatimes
- 565
- May 4, 2017
IATI Market Views WHO
NICE nods for Amgen’s rare leukaemia drug

Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
- Source: pharmatimes
- 641
- May 3, 2017
cancer Company Insight NHS NICE therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.